An interventional study of blood microsampling in Alcohol Drinking and Binge Drinking, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 18 Years to 25 Years. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by Centre Hospitalier Universitaire, Amiens · Not applicable, Interventional, and Prevention
Alcohol use is a causal factor in more than 200 diseases and injury conditions (see ICD-10) and in France, alcohol is the first cause of hospitalization. Binge drinking (BD) has emerged as a major public health issue among student populations and is associated with negative consequences and social, cognitive and brain alterations. More than half of French university students have reported BD in the past month and are at increased risk of several alcohol-related consequences such as memory and sleep impairments, and reduced quality of life. BD is also a major risk factor in the development of alcohol addiction, with individual and environmental factors playing a role that is still poorly understood. Moreover, most students and young adults are reluctant to seek interventions when it is provided by health care professionals (only 4-5%) and have poor insight with regard to their alcohol use patterns / habits. Thus, there is an urgent need for developing effective prevention and intervention programs to reduce alcohol drinking in students. Recent studies have demonstrated that new types of technology-delivered interventions are promising tools for addressing unhealthy alcohol use. For example, an uncontrolled trial pilot study using a smartphone application-delivered intervention produced a reduction in both number of drinks per week and BD from baseline to 3-month follow-up. A recent review also showed significant outcomes of a mobile health intervention for self-control of unhealthy alcohol use. The investigators hypothesize that a timeline follow-back and personalized feedback based on the use of a mobile application can reduce excessive alcohol intake at 3-months. This study will provide scientific knowledge about BD in students, but also regarding a new type of intervention that could be effective for prevention in non-treatment seeking individuals and reducing the severity of health problems associated with excessive alcohol intake.
71 studies on the registry are indexed under Binge Drinking; 20 are open to participants now.
This study's planned enrollment of 628 is above the median of 120 across 64 interventional studies indexed under Binge Drinking.
Browse Binge Drinking studies →Centre Hospitalier Universitaire, Amiens is the lead sponsor of 586 studies on the registry; 185 are open to participants now.
Compared within Binge Drinking, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Alcohol Drinking. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biological: blood microsampling
Biological: blood microsampling
blood microsampling for the measure of Phosphatidylethanol
Change of the number of standard drinks per week
Time frame: 30 months
Change of the PEth concentration
phosphatidylethanol (PEth)
Time frame: 3 months
Change of the PEth concentration
phosphatidylethanol (PEth)
Time frame: 6 months
Change of the PEth concentration
phosphatidylethanol (PEth)
Time frame: 9 months
Change of the PEth concentration
phosphatidylethanol (PEth)
Time frame: 12 months
Change of the PEth concentration
phosphatidylethanol (PEth)
Time frame: 15 months
Change of the PEth concentration
phosphatidylethanol (PEth)
Time frame: 18 months
Change of the PEth concentration
phosphatidylethanol (PEth)
Time frame: 21 months
Change of the PEth concentration
phosphatidylethanol (PEth)
Time frame: 24 months
Change of the PEth concentration
phosphatidylethanol (PEth)
Time frame: 27 months
Change of the PEth concentration
phosphatidylethanol (PEth)
Time frame: 30 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire, Amiens →